AGRX Agile Therapeutics, Inc.

3.05
+0  (1%)
Previous Close 3.02
Open 3.05
Price To book 2.05
Market Cap 87.77M
Shares 28,776,000
Volume 85,473
Short Ratio 6.26
Av. Daily Volume 275,542

SEC filingsSee all SEC filings

  1. 8-K - Current report 17764851
  2. 8-K - Current report 17756229
  3. 8-K - Current report 17695041
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17691737
  5. 8-K - Current report 17675373

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Phase 3 top-line data released January 3, 2017 - poor data but reconfirmed April 11, 2017 its intention to reflile NDA 2Q 2017.
Twirla
Contraceptive patch

Latest News

  1. Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
  2. Agile Therapeutics (AGRX) Catches Eye: Stock Moves Up 14%
  3. Agile Therapeutics reports 4Q loss
  4. Agile Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
  5. IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  6. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) & Lead Plaintiff Deadline - March 7, 2017
  7. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agile Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AGRX
  8. UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Agile Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 7, 2017
  9. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Agile Therapeutics, Inc. - AGRX
  10. Agile Therapeutics to Present at 29th Annual ROTH Conference
  11. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) and Lead Plaintiff Deadline - March 7, 2017
  12. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  13. DEADLINE ALERT: Brower Piven Reminds Investors Of The March 7, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Agile Therapeutics, Inc. To Contact The Firm
  14. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  15. AGRX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Agile Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017
  16. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in Agile Therapeutics, Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline
  17. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  18. Investor Alert: GPM Reminds Investors of the March 7 Deadline in the Class Action Lawsuit Against Agile Therapeutics, Inc.
  19. Pawar Law Group Announces that a Securities Class Action Lawsuit has been filed Against Agile Therapeutics, Inc. - AGRX
  20. SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm